牛牛AI助理已提取核心訊息
On February 29, 2024, TC BioPharm (Holdings) PLC, an emerging growth company listed on The Nasdaq Stock Market, reported a significant update to its executive compensation structure. The company's Remuneration Committee approved the issuance of new options to purchase American Depositary Shares (ADSs) to its executive officers and non-employee directors under the 2021 Shares Option Scheme. This move also included the cancellation of all previously issued share options to these individuals. Non-employee directors were granted options to purchase 41,760 ADSs each, while the CFO, Martin Thorp, received options for 177,122 ADSs, and the CEO, Bryan Kobel, was granted options for 381,606 ADSs. The exercise price for these options was set at $1.09 per ADS, equivalent to the closing price on January 31, 2024. All options vested immediately upon issuance. This strategic decision aligns with the company's aim to incentivize its leadership team and align their interests with those of the shareholders.
On February 29, 2024, TC BioPharm (Holdings) PLC, an emerging growth company listed on The Nasdaq Stock Market, reported a significant update to its executive compensation structure. The company's Remuneration Committee approved the issuance of new options to purchase American Depositary Shares (ADSs) to its executive officers and non-employee directors under the 2021 Shares Option Scheme. This move also included the cancellation of all previously issued share options to these individuals. Non-employee directors were granted options to purchase 41,760 ADSs each, while the CFO, Martin Thorp, received options for 177,122 ADSs, and the CEO, Bryan Kobel, was granted options for 381,606 ADSs. The exercise price for these options was set at $1.09 per ADS, equivalent to the closing price on January 31, 2024. All options vested immediately upon issuance. This strategic decision aligns with the company's aim to incentivize its leadership team and align their interests with those of the shareholders.
2024年2月29日，在納斯達克股票市場上市的新興成長型公司TC BioPharm（Holdings）PLC報告了其高管薪酬結構的重大更新。該公司的薪酬委員會批准了根據2021年股票期權計劃向其執行官和非僱員董事發行購買美國存托股票（ADS）的新期權。此舉還包括取消先前向這些人發行的所有股票期權。非僱員董事獲准每人購買41,760份美國存託證券的期權，而首席財務官馬丁·索普獲得了177,122份美國國債的期權，首席執行官布萊恩·科貝爾獲得了381,606份美國存託證券的期權。這些期權的行使價定爲每份ADS1.09美元，相當於2024年1月31日的收盤價。所有期權在發行後立即歸屬。這一戰略決策符合公司的目標，即激勵其領導團隊，使他們的利益與股東的利益保持一致。
2024年2月29日，在納斯達克股票市場上市的新興成長型公司TC BioPharm（Holdings）PLC報告了其高管薪酬結構的重大更新。該公司的薪酬委員會批准了根據2021年股票期權計劃向其執行官和非僱員董事發行購買美國存托股票（ADS）的新期權。此舉還包括取消先前向這些人發行的所有股票期權。非僱員董事獲准每人購買41,760份美國存託證券的期權，而首席財務官馬丁·索普獲得了177,122份美國國債的期權，首席執行官布萊恩·科貝爾獲得了381,606份美國存託證券的期權。這些期權的行使價定爲每份ADS1.09美元，相當於2024年1月31日的收盤價。所有期權在發行後立即歸屬。這一戰略決策符合公司的目標，即激勵其領導團隊，使他們的利益與股東的利益保持一致。
有用
沒用